BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17364559)

  • 1. Role of pemetrexed in non-small cell lung cancer.
    Longo-Sorbello GS; Chen B; Budak-Alpdogan T; Bertino JR
    Cancer Invest; 2007 Feb; 25(1):59-66. PubMed ID: 17364559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
    Molina JR; Adjei AA
    Clin Lung Cancer; 2003 Jul; 5(1):21-7. PubMed ID: 14596699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed for the treatment of non-small-cell lung cancer.
    Manegold C; Schmid-Bindert G; Pilz LR
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1195-209. PubMed ID: 19761423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
    Adjei AA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
    Scagliotti GV; Selvaggi G
    Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed in first-line treatment of non-small cell lung cancer.
    Esteban E; Casillas M; Cassinello A
    Cancer Treat Rev; 2009 Jun; 35(4):364-73. PubMed ID: 19269106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Update of pemetrexed in thoracic oncology].
    Brechot JM; Morère JF
    Bull Cancer; 2007; 94 Spec No Actualites():S139-41. PubMed ID: 17845984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study.
    Bearz A; Garassino I; Cavina R; Favaretto A; Boccalon M; Talamini R; Berretta M; Spazzapan S; Simonelli C; Santoro A; Tirelli U
    Lung Cancer; 2008 May; 60(2):240-5. PubMed ID: 18022729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
    Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
    Sun JM; Lee KW; Kim JH; Kim YJ; Yoon HI; Lee JH; Lee CT; Lee JS
    Jpn J Clin Oncol; 2009 Jan; 39(1):27-32. PubMed ID: 18952704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: a phase I-II trial.
    Stathopoulos GP; Dimitroulis J; Toubis M; Katis C; Karaindros D; Stathopoulos J; Koutandos J
    Lung Cancer; 2007 Jul; 57(1):66-71. PubMed ID: 17382431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Second-line treatment of advanced non-small-cell lung cancer: role of pemetrexed].
    Pérol M
    Rev Pneumol Clin; 2005 Sep; 61(4 Pt 2):4S14-7. PubMed ID: 16273004
    [No Abstract]   [Full Text] [Related]  

  • 14. New developments in chemotherapy for advanced non-small cell lung cancer.
    Raez LE; Lilenbaum R
    Curr Opin Oncol; 2006 Mar; 18(2):156-61. PubMed ID: 16462185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial.
    Ferraldeschi R; Thatcher N; Lorigan P
    Expert Rev Anticancer Ther; 2007 May; 7(5):635-40. PubMed ID: 17492928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer.
    Ohe Y; Ichinose Y; Nakagawa K; Tamura T; Kubota K; Yamamoto N; Adachi S; Nambu Y; Fujimoto T; Nishiwaki Y; Saijo N; Fukuoka M
    Clin Cancer Res; 2008 Jul; 14(13):4206-12. PubMed ID: 18594001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of MTA in the treatment of non-small cell lung cancer.
    Postmus PE; Green MR
    Semin Oncol; 1999 Feb; 26(1 Suppl 4):31-6. PubMed ID: 10201519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pemetrexed: from preclinic to clinic].
    Lansiaux A; Lokiec F
    Bull Cancer; 2007; 94 Spec No Actualites():S134-8. PubMed ID: 17845983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study of use of pemetrexed in non-small cell lung cancer].
    Villanueva-Herraiz S; Ortega-García MP; Camps-Herrero C; Blasco-Segura P
    Farm Hosp; 2010; 34(4):194-203. PubMed ID: 20594885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboplatin-pemetrexed adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): a phase II study.
    Karapanagiotou EM; Boura PG; Papamichalis G; Konstantinou M; Sepsas E; Chamalakis G; Simsiris P; Gkiozos I; Syrigos KN
    Anticancer Res; 2009 Oct; 29(10):4297-301. PubMed ID: 19846990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.